share_log

iBio Inc | SC 13G: Statement of acquisition of beneficial ownership by individuals-Ikarian Capital, LLC(6.6%),Neil Shahrestani(6.6%)

iBio Inc | SC 13G: Statement of acquisition of beneficial ownership by individuals-Ikarian Capital, LLC(6.6%),Neil Shahrestani(6.6%)

iBio Inc | SC 13G：超过5%持股股东披露文件-Ikarian Capital, LLC(6.6%),Neil Shahrestani(6.6%)
美股SEC公告 ·  2024/11/15 09:51

Moomoo AI 已提取核心信息

iBio Inc, a biotechnology company, has been the subject of a Schedule 13G filing with the U.S. Securities and Exchange Commission (SEC), indicating a significant acquisition of shares by Ikarian Capital, LLC and Neil Shahrestani. The filing, dated September 30, 2024, and disclosed on November 14, 2024, reports that Ikarian Capital and Shahrestani collectively hold 599,913 shares of iBio Inc's common stock, representing 6.6% of the company's total shares outstanding as of November 12, 2024. Ikarian Capital, a Delaware-based investment adviser, manages these shares through the Ikarian Healthcare Master Fund, L.P., and certain separately managed accounts. Neil Shahrestani, who has indirect control over Ikarian Capital, is also reported as a beneficial owner of the shares. The filing emphasizes that this acquisition does not aim to change or influence the control of iBio Inc.
iBio Inc, a biotechnology company, has been the subject of a Schedule 13G filing with the U.S. Securities and Exchange Commission (SEC), indicating a significant acquisition of shares by Ikarian Capital, LLC and Neil Shahrestani. The filing, dated September 30, 2024, and disclosed on November 14, 2024, reports that Ikarian Capital and Shahrestani collectively hold 599,913 shares of iBio Inc's common stock, representing 6.6% of the company's total shares outstanding as of November 12, 2024. Ikarian Capital, a Delaware-based investment adviser, manages these shares through the Ikarian Healthcare Master Fund, L.P., and certain separately managed accounts. Neil Shahrestani, who has indirect control over Ikarian Capital, is also reported as a beneficial owner of the shares. The filing emphasizes that this acquisition does not aim to change or influence the control of iBio Inc.
ibio inc是一家生物技术公司，已向美国证券交易委员会（SEC）提交了Schedule 13G文件，显示Ikarian Capital, LLC和Neil Shahrestani对其股票进行了大规模收购。该文件日期为2024年9月30日，并于2024年11月14日披露，报告称Ikarian Capital和Shahrestani共同持有ibio inc的普通股599,913股，代表于2024年11月12日公司总流通股的6.6%。Ikarian Capital是一家位于特拉华州的投资顾问，通过Ikarian Healthcare Master Fund, L.P.及某些单独管理的账户管理这些股票。Neil Shahrestani间接控制Ikarian Capital，并被报告为这些股票的实益拥有者。该文件强调此次收购并不旨在改变或影响ibio inc的控制权。
ibio inc是一家生物技术公司，已向美国证券交易委员会（SEC）提交了Schedule 13G文件，显示Ikarian Capital, LLC和Neil Shahrestani对其股票进行了大规模收购。该文件日期为2024年9月30日，并于2024年11月14日披露，报告称Ikarian Capital和Shahrestani共同持有ibio inc的普通股599,913股，代表于2024年11月12日公司总流通股的6.6%。Ikarian Capital是一家位于特拉华州的投资顾问，通过Ikarian Healthcare Master Fund, L.P.及某些单独管理的账户管理这些股票。Neil Shahrestani间接控制Ikarian Capital，并被报告为这些股票的实益拥有者。该文件强调此次收购并不旨在改变或影响ibio inc的控制权。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Enveric Biosciences
    ENVB
    -- 2.3000
    Renovaro
    RENB
    -- 1.190
    Moolec Science
    MLEC
    -- 0.850
    Salarius Pharmaceuticals
    SLRX
    -- 1.4500
    Channel Therapeutics
    CHRO
    -- 2.230
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    特斯拉绩后巨震，后市你怎么看？
    特斯拉2024年Q4营收257.1亿美元，同比增长2%，不及预期。Cybercab计划2026年投产，预计车辆业务将于2025年恢复增长。面对特朗普回归，特斯拉股价能否在2025年继续攀升？ 展开
    TSLA财报预告：通过猜测开盘价来获取奖励！